Ribbon형 Co1-x Crx (x=0.27, 0.29, 0.30, 0.32, 0.35) 합금의 자기특성

장현숙,김미양,이장로,이용호 숙명여자대학교 자연과학연구소 1994 자연과학논문집 Vol.- No.5

급냉법으로 리본형 결정질 Co1-x Crx (x=0.27, 0.29, 0.30, 0.32, 0.35)합금을 제조하여 Cr의 조성에 따른 자기적 특성을 조사하였다. 포화자화값은 벌크값보다 컸지만 박막의 경우보다는 작았다. Cr의 함량이 증가함에 따라 포화자화값은 감소하였다. 27 at.% Cr의 경우를 예외로 하면 Cr 함량 증가에 따라 결정립의 크기는 감소하였고, 항자력은 증가하였다. 리본형 Co1-x Crx 는 포화자화값의 온도 의존성이 비정질 시료인 경우와 유사한 경향을 나타내었으며 Cr의 함량이 증가할수록 Curie온도(Tr)는 감소하였다. Cr 함량의 증가에 따라 exchange interaction의 평균자승거리<r²>와 spin wave stiffness 상수D는 감소하는 경향을 나타내었다. 천이금속(Co)의 원자당평균 자기모멘트는 Cr의 증가에 따라 선형적으로 감소하였다. The magnetic cnaracteristics of crystalline Co1-x Crx (x=0.27, 0.29, 0.30, 0.32, 0.35) ribbons prepared by the rapid solidification were investigated. The saturation magnetization for ribbon was greater than that for bulk alloys containg the same amount of Cr. but smaller for the films. The grain size of ribbon became smaller and coercive force increased with increasing Cr contents except case of 27 at.% Cr. The saturation magnetization decreased with increasing Cr contensts. The temperature dependence of saturation magnetization for Co1-x Crx ribbon showed the similar behavior as the amorphous alloy and the Curie temperatures were decreased with the increase of Cr contents. The spin wave stiffness constant and the mean square range of exchange interaction, also were decreased. The average magnetic moment per transition metal atom was linearly decreased with increasing the contents of Cr.

Molecular Pathology of Lung Cancer: Current Status and Future Directions

Roh, Mee Sook The Korean Academy of Tuberculosis and Respiratory 2014 Tuberculosis and Respiratory Diseases Vol.77 No.2

The rapid development of targeted therapies has enormously changed the clinical management of lung cancer patients over the past decade; therefore, molecular testing, such as epidermal growth factor receptor (EGFR) gene mutations or anaplastic lymphoma kinase (ALK) gene rearrangements, is now routinely used to predict the therapeutic responses in lung cancer patients. Moreover, as technology and knowledge supporting molecular testing is rapidly evolving, the landscape of targetable genomic alterations in lung cancer is expanding as well. This article will summarize the current state of the most commonly altered and most clinically relevant genes in lung cancer along with a brief review of potential future developments in molecular testing of lung cancer.

Gene Expression Profiling of Non-Small Cell Lung Cancer

Mee Sook Roh,Hyuk Chan Kwon,Jin Sook Jeong,Dae Cheol Kim,Choon Hee Son,Soo Keol Lee,Phil Jo Choi,Jae Ik Lee,Ki Nam Lee,Hyo Jin Kim,Jin Han Yoon,Tae Ho Hwang 대한암학회 2003 Cancer Research and Treatment Vol.35 No.2

Purpose: cDNA microarray provided a powerful alternative,with an unprecedented view scope, in monitoringgene expression levels, and led to the discoveryof regulatory pathways involved in complicated biologicalprocesses. This study w as performed to gainbetter understanding of the molecular mechanismsunderlying the carcinogenesis and progression oflung cancer.Materials and Methods: Using a cDNA microarray,representing 4,600 cDNA clusters, we studied the expressionprofiles in 10 non-small cell lung cancer (NSCLC)samples and the adjacent noncancerous lung tissuesform the same patients. The alterations in the levelsof gene expression were confirmed by reverse-transcriptionPCR in 10 randomly selected genes.Results: Genes that were differently expressed in thecancerous and noncancerous tissues were identified.One hundred and nine genes (of which 68 were known)and 69 cDNAs (of which 32 were known) were up- anddown-regulated in 〉70% of the NSCLC samples, respectively.In the cancerous tissues, the genes related tothe cell cycle, metabolism, cell structure and signaltransduction, were mostly up-regulated. Furthermore,we identified a few putative tumor suppressor genesthat had previously been proposed by other workers.Conclusions: These results provide, not only a newmolecular basis for understanding the biological propertiesof NSCLC, but also useful resources for thefuture development of diagnostic markers and therapeutictargets for NSCLC. (Cancer Res Treat. 2003;35:154-160)

REVIEW : Molecular Pathology of Lung Cancer: Current Status and Future Directions

( Mee Sook Roh ) 대한결핵 및 호흡기학회 2014 Tuberculosis and Respiratory Diseases Vol.77 No.2

The rapid development of targeted therapies has enormously changed the clinical management of lung cancer patients over the past decade, therefore, molecular testing, such as epidermal growth factor receptor (EGFR) gene mutations or anaplastic lymphoma kinase (ALK) gene rearrangements, is now routinely used to predict the therapeutic responses in lung cancer patients. Moreover, as technology and knowledge supporting molecular testing is rapidly evolving, the landscape of targetable genomic alterations in lung cancer is expanding as well. This article will summarize the current state of the most commonly altered and most clinically relevant genes in lung cancer along with a brief review of potential future developments in molecular testing of lung cancer.

Loss of PTEN Expression in Primary Lung Cancer

Mee Sook Roh 대한병리학회 2002 Journal of Pathology and Translational Medicine Vol.36 No.5

Background : The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) gene, a candidate tumor suppressor, is localized to chromosome 10q23 and shares extensive homology with cytoskeletal proteins auxilin and tensin. It appears to have multifunctional roles involved in cell proliferation, migration, and invasion. The role of PTEN alteration in the lung cancer and its relationship with other suppressor genes are not well established. Methods : Formalin-fixed, paraffin-embedded tissues from 105 patients with diagnosed with primary lung cancer were evaluated for PTEN and p53 protein expression using immunohistochemical methods. The results of the expression pattern of PTEN were compared with clinicopathological parameters and the expression pattern of p53. Results : Forty-seven (44.8%) of 105 cases had loss of PTEN expression. Loss of PTEN expression was significantly associated with histologic type (p<0.05), but did not correlate with tumor size, lymph node metastasis, and stage. There was no significant relationship between loss of PTEN expression and p53 expression, and no significant difference in clinicopathologic characteristics between particular groups of patterns with the four possible tumor carrying PTEN/p53 phenotypes. Conclusion : It is suggested that loss of PTEN expression occurs commonly in primary lung cancers and correlates with histologic type. Our results also support the proposed role of PTEN as a candidate tumor suppressor in lung cancer, and we suggest that there is a need for further study of this gene.

Expression of miR-200c and its clinicopathological significance in patients with colorectal cancer

Roh, Mee Sook,Lee, Hyoun Wook,Jung, Sang Bong,Kim, Kyungeun,Lee, Eun Hee,Park, Moon-il,Lee, Jae Seok,Kim, Mee-Seon Elsevier 2018 Pathology, research and practice Vol.214 No.3

<P>MicroRNA-200c (miR-200c) is known to play a pivotal role in the regulation of epithelial-to-mesenchymal and mesenchymal-to-epithelial transition processes. However, the biological function of miR-200c in human carcinogenesis remains controversial. We examined the association of miR-200c expression with various clinicopathological factors, including KRAS mutation status and survival, in patients with colorectal cancer (CRC). The expression level of miR-200c was evaluated in 109 paired CRC and normal tissue samples using quantitative reverse transcription polymerase chain reaction. The KRAS mutation status of the CRC samples was determined using the PNAClamp (TM) KRAS Mutation Detection kit. Compared with the normal tissue group, miR-200c expression was significantly upregulated in the CRCs (P<.001). The expression of miR-200c was increased in CRCs with higher grade (P=.009), advanced stage (P=.042), and lymphovascular invasion (P=.003). Thirty-one CRCs (28.4%) had KRAS mutations in codon 12 or 13. CRCs with KRAS mutations had significantly higher miR-200c expression than CRCs with wild-type KRAS (P=.003). In survival analysis, high miR-200c expression was correlated with worse overall survival (P=.017) and recurrence-free survival (P=.048). Our results indicate that miR-200c is involved in tumor progression and aggressiveness in CRCs, and this oncogenic role of miR-200c may be triggered by activation of the KRAS signaling pathway.</P>

Primary Carcinosarcoma of the Skin : A Case Report

Roh, Mee Sook,Huh, Gi Yeong,Hong, Sook Hee 대한병리학회 2001 Journal of Pathology and Translational Medicine Vol.35 No.4

Relationship between PTEN and Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Cancer

Mee Sook Roh,Jae Ik Lee,Doo Kyung Yang,Soo Keol Lee,Hyuk Chan Kwon,Mi Kyoung Park,Ki Baek Hwang,Jin A Jung 대한암학회 2003 Cancer Research and Treatment Vol.35 No.5

수술 절제를 시행받은 제1기 비소세포폐암 환자에서의 Fascin 발현과 예후

노미숙 ( Mee Sook Roh ),엄수정 ( Su Jung Um ),최영민 ( Young Min Choi ),김기남 ( Ki Nam Kim ),최필조 ( Pil Jo Choi ),이수걸 ( Soo Keol Lee ),손춘희 ( Choon Hee Son ),양두경 ( Doo Kyung Yang ) 대한결핵 및 호흡기학회 2008 Tuberculosis and Respiratory Diseases Vol.65 No.2

연구배경: Fascin은 세포 운동에 관여하는 액틴 결합 단백질로서 정상적인 상피세포에는 증가되어 있지 않으며, 일부 악성종양에서 fascin이 증가되어 있다는 보고가 있다. 본 연구는 비소세포폐암 환자의 조직에서 fascin 발현을 조사하고 fascin이 예후 인자로 역할을 하는지를 알아보고자 하였다. 방법: 제 1기 비소세포폐암으로 근치적 절제수술을 받고 추적조사가 가능했던 환자 81명의 조직에서 fascin 발현을 면역조직화학 염색 방법으로 조사하였다. 결과: Fasin 발현은 전체 81예 중 59예(73%)에서 양성이었다. Fascin 발현 정도에 따른 5년 생존율은 fascin 발현 음성군에서 68%, fascin 저발현군에서 76%, fascin고발 현군에서 79%으로 각 군간에 유의한 차이가 없었다(p=0.86). 결론: Fascin 발현이 비소세포폐암으로 근치적 수술을 받은 환자에서 예후 인자로서 역할을 하는지 알아보았으나 통계학적으로 유의한 관련성이 없었다. Background: Fascin is an actin-bundling protein that plays an important role in cellular motility. Fascin is normally expressed in the neuronal and mesenchymal cells and its expression is low or absent in the epithelia. However, an overexpression of fascin has been linked to the invasive behavior of some neoplasms such as breast, stomach and ovarian tumors. In this study, we evaluated the expression of fascin and its prognostic significance in stage I non-small cell lung cancer (NSCLC). Methods: Immunohistochemical staining for fascin was performed on the paraffin-embeded tissue sections of 81 cases of resected NSCLC. Staining of more than 5% of the tumor cells was recorded as positive immunoreactivity. Results: Fascin expression was seen in 73% (59/81) of the cases and this was more frequently seen in squamous cell carcinoma than in adenocarcinoma (93% vs 42%). There were no significant correlations of fascin immunoreactivity with tumor recurrence and overall survival. Conclusion: The expression rate of fascin was relatively high in NSCLC, but this was without prognostic significance. The exact clinical role of fascin should be defined through further investigations. (Tuberc Respir Dis 2008;65: 105-109)

Gene Expression Profiling of Breast Cancers with Emphasis of beta-Catenin Regulation

Jeong Jin Sook,Cho Se Heon,Hong Sook Hee,Kwon Hyuk Chan,Kim Min Chan,Yoon Jin Han,Hwang Tae Ho,Roh Mee Sook 대한의학회 2004 Journal of Korean medical science Vol.19 No.2